--- title: "BPC-157" url: "https://lotuspeptide.com/peptide/bpc-157" canonical: "https://lotuspeptide.com/peptide/bpc-157" type: "product" brand: "LotusPeptide" category: "Peptides" strengths: "5 mg and 10 mg" currency: "USD" price_low: "20.00" price_high: "220.00" availability: "out of stock" ships_from: "United States" handling_time_business_days: 1 returns: "not accepted" replacements_and_refunds: "damaged or lost items" intended_use: "Laboratory research use only" image: "https://lotuspeptide.com/order/api/media/products/2.webp?size=full&v=1" updated: "2026-10-05" synonyms: "Body protection compound 157; BPC 157; PL 14736; PLD-116; Bepecin" cas: "137525-51-0 (free base)" formula: "C62H98N16O22" molecular_weight: "1419.5 g/mol" sequence: "Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)" pubchem: "9941957" written_by: "LotusPeptide research team" --- # BPC-157 > Research grade. Lyophilised powder, 5mg per vial. ## Strengths, packs and prices ### 5 mg - Page: https://lotuspeptide.com/peptide/bpc-157?strength=5mg - Availability: Out of stock | Pack | Price | Per vial | |---|---|---| | Single Vial | $20 | $20 | | 5-Pack (5 vials) | $90 | $18 | | 10-Pack (10 vials) | $170 | $17 | ### 10 mg - Page: https://lotuspeptide.com/peptide/bpc-157?strength=10mg - Availability: Out of stock | Pack | Price | Per vial | |---|---|---| | Single Vial | $30 | $30 | | 5-Pack (5 vials) | $135 | $27 | | 10-Pack (10 vials) | $220 | $22 | ## At a glance - Strengths: 5 mg and 10 mg - Category: Peptides - Also known as: Body protection compound 157; BPC 157; PL 14736; PLD-116; Bepecin - CAS number: 137525-51-0 (free base) - Molecular formula: C62H98N16O22 - Molecular weight: 1419.5 g/mol - Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) - PubChem CID: 9941957 - Availability: Out of stock - Ships from: United States - Intended use: Laboratory research use only - Page updated: 2026-10-05 Written by LotusPeptide research team. BPC-157 is a synthetic linear peptide of 15 amino acids, GEPPPGKPADDAGLV, derived from a fragment of a protein found in gastric juice [1]. It is not an FDA-approved drug and is not part of any approved product; it is sold here only as a laboratory research material. ## What BPC-157 is BPC-157 is a pentadecapeptide whose name abbreviates "body protection compound-157" [2]. A 2026 review describes it as a synthetic peptide derived from a gastric protein fragment, noted for unusual stability in gastric juice [1]. FDA's 2026 briefing document for its compounding advisory committee states that researchers at the University of Zagreb first synthesised it in the early 1990s. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It has a free amino terminus and a free carboxylic acid terminus, a run of three prolines near the start, one lysine and three acidic residues. PubChem lists the development codes PL-10, PLD-116 and PL-14736 among its synonyms, together with the name Bepecin. FDA's briefing describes human studies of the peptide under the code PL 14736 reported between 2002 and 2005. ## Chemical identity and salt forms BPC-157 as the free peptide is PubChem CID 9941957, with molecular formula C62H98N16O22, an average molecular weight of 1419.5 g/mol and CAS number 137525-51-0. Its monoisotopic mass in PubChem is 1418.704 Da, so the singly protonated ion in mass spectrometry falls near m/z 1419.7. FDA's 2026 briefing lists BPC-157 acetate under a separate CAS number, 216441-37-1, and classes the free base and the acetate as different bulk substances. FDA also reported that nomination packages named the free base while the attached certificates described the acetate. PubChem additionally lists a trifluoroacetate salt among its synonyms. The practical point for a researcher is that the labelled milligrams of a vial can include counterions and water. The certificate should therefore state which form is present and how much of the mass is peptide. ## Regulatory status No FDA-approved drug contains BPC-157. FDA's 2026 briefing states that there is no United States Pharmacopeia or National Formulary monograph for it and that it is not a component of an approved drug. BPC-157 free base and BPC-157 acetate were on the agenda of FDA's Pharmacy Compounding Advisory Committee meeting of July 23, 2026, which considered substances for the list of bulk drug substances usable in compounding under section 503A. As of October 3, 2026, FDA had not published minutes of that meeting or a decision. A 2025 systematic review notes that BPC-157 lacks FDA approval and that its use is banned in professional sports [2]. An anti-doping laboratory has published a validated method to detect it in urine [3]. The material sold here is a research chemical for laboratory work and is not a medicine. ## Published research Most published BPC-157 work is preclinical. A 2025 systematic review of the musculoskeletal literature identified 544 articles and included 36 studies after screening, of which 35 were preclinical and one was clinical [2]. A 2026 review of its pharmaceutical development summarises a formal absorption, distribution, metabolism and excretion study in two animal species. That study reported a plasma half-life under 30 minutes and linear kinetics [1]. The same review counts fewer than 30 human subjects across three uncontrolled pilot studies, none using a standardised pharmaceutical preparation [1]. FDA's 2026 briefing describes further human studies reported only as meeting abstracts. These were placebo-controlled phase 1 studies in healthy subjects (32 randomised) and a multicentre, randomised, double-blind, placebo-controlled study (53 randomised). FDA also found a registered phase 1 study in healthy subjects (NCT02637284) with no posted results. In an in vitro study, an anti-doping laboratory examined how BPC 157 is broken down in plasma and identified a stable metabolite [3]. ## What is not known The main gap is controlled human evidence published in full. No report of a controlled human trial of BPC-157 is indexed in PubMed as of October 2026. The controlled studies FDA describes exist only as meeting abstracts, which FDA notes lack many trial details. A 2026 review reports no completed phase 2 trial and no validated pharmaceutical formulation [1]. The 2025 systematic review found no clinical safety data [2]. Human pharmacokinetics remain largely uncharacterised [1]. The short half-life measured in animals has not been reconciled with the longer-lasting effects reported in animal models [1]. No formal excipient compatibility or permeability studies have been published [1]. Little is published on the composition of material sold outside regulated channels. An anti-doping laboratory identified BPC 157 in confiscated vials in 2017 [3], and FDA found the salt form inconsistently described in nomination documents. ## Laboratory storage and handling Lyophilised BPC-157 should be stored as stated on the certificate of analysis and the product label. FDA's 2026 briefing summarises published supplier information for the lyophilised free base. It was reported stable at room temperature for about three weeks, with storage desiccated below minus 18 °C recommended because moisture lowers long-term stability. These figures are supplier data quoted by FDA, not a peer-reviewed stability study. Synthetic peptides can accumulate impurities from their storage conditions as well as from their manufacture [4]. Material held for a long time is therefore worth re-testing before use in an experiment. A 2026 review found no formal excipient compatibility studies for BPC-157, so published data on its behaviour in prepared formulations are lacking [1]. ## Quality testing A certificate of analysis for BPC-157 should confirm identity by mass spectrometry. The main ion should match the expected mass, near m/z 1419.7 for the singly protonated peptide or near m/z 710.4 for the doubly protonated form. Purity should be measured by reversed-phase HPLC with UV detection, and the chromatogram should show the main peak and the impurity peaks. The certificate should name the salt form, report counterion content (acetate or trifluoroacetate) and water, and give a peptide content or assay value. LC-MS can characterise impurities of synthetic peptides, including structural isomers and epimers [4]. FDA noted in 2026 that certificates in the nomination packages and the public domain often lacked tests for impurities, aggregates and bacterial endotoxins. Each batch's own certificate, not this article, carries the purity result. ## Questions ### Is BPC-157 the same as the BPC protein found in gastric juice? No. BPC-157 is a 15-amino-acid synthetic peptide derived from a fragment of that gastric protein, not the whole protein [1]. ### What is the difference between BPC-157 free base and BPC-157 acetate? They contain the same 15-residue peptide. The acetate form also carries acetic acid counterions, so it has a different CAS number (216441-37-1 in FDA's 2026 briefing) and a higher mass per mole of peptide. FDA regards the two as distinct bulk substances, and a certificate should say which one a batch is. ### Has BPC-157 been tested in controlled human trials? No full report of a controlled human trial is indexed in PubMed as of October 2026. A 2026 review counts three small uncontrolled pilot studies [1]. FDA's 2026 briefing describes earlier placebo-controlled studies that were reported only as meeting abstracts. ## References 1. [Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026.](https://pubmed.ncbi.nlm.nih.gov/42198317/) 2. [Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025.](https://pubmed.ncbi.nlm.nih.gov/40756949/) 3. [Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017.](https://pubmed.ncbi.nlm.nih.gov/28035768/) 4. [Lian Z, Wang N, Tian Y, et al. Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives. J Am Soc Mass Spectrom. 2021.](https://pubmed.ncbi.nlm.nih.gov/34110145/) _This page summarises published laboratory research and cites its sources. It is not medical advice and makes no claim that the compound treats, cures or prevents any condition. LotusPeptide sells it for laboratory research use only._ ## Shipping and returns - Orders are processed and shipped within 1 business day. - Returns are not accepted. - Replacements and refunds are offered on damaged or lost items. ## Related products - [TB-500](https://lotuspeptide.com/peptide/tb-500.md): from $25 - [BPC-157+TB500 (Blend) 10mg](https://lotuspeptide.com/peptide/bpc-157-tb500-blend.md): from $35 - [GHK-Cu](https://lotuspeptide.com/peptide/ghk-cu.md): from $20 --- For laboratory research use only. Not for human or veterinary use. Prices are in US dollars and can change without notice.